

What is claimed is:

1. A method for treating a patient diagnosed with an ophthalmic disease caused by premature stop mutations in a gene, wherein the method comprises administering to such patient a composition comprising an aminoglycoside antibiotic compound.
2. The method of Claim 1 wherein the ophthalmic disease is glaucoma.
3. The method of Claim 2 wherein the patient is diagnosed with a stop mutation in a gene selected from the group consisting of GLC1A and CYP1B1.
4. A method for treating a patient diagnosed with an ophthalmic disease caused by premature stop mutations in a gene, wherein the method comprises locally administering to the eye of such patient a composition comprising an aminoglycoside antibiotic compound.
5. The method of Claim 4 wherein the ophthalmic disease is glaucoma.
6. The method of Claim 5 wherein the patient is diagnosed with a stop mutation in a gene selected from the group consisting of GLC1A and CYP1B1.
7. The method of Claim 5 wherein the aminoglycoside antibiotic is selected from the group consisting of gentamicin; tobramycin; metilmicin; amilcacin; kanamycins A and B; streptomycin; netilmicin; and neomycin.
8. The method of Claim 5 wherein the composition is topically administered as an eye drop.
9. The method of Claim 8 wherein the aminoglycoside antibiotic compound is present in the composition in an amount of 1% (w/w) or less.

10. The method of Claim 9 wherein the aminoglycoside antibiotic compound is present in the composition in an amount of 0.2 – 0.4% (w/w).

20220722 22:55:07